A Phase 2/3, multicenter, randomized, double-blinded, placebo-controlled, repeat???dose study to evaluate the efficacy, safety, pharmacodynamics, and pharmacokinetics of olipudase alfa in patients with acid sphingomyelinase deficiency
|Effective start/end date||2/13/17 → 2/28/22|
- GENZYME CORPORATION
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.